{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:05:04Z","timestamp":1790712304913,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007657","name":"Loyola University Chicago Stritch School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010201","name":"USAMRIID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010201","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ijbiomac.2021.04.148","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T11:54:08Z","timestamp":1619438048000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy"],"prefix":"10.1016","volume":"183","author":[{"given":"Yash","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Maciorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Zak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrashekhar V.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Durvasula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakasha","family":"Kempaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000571","article-title":"Estimated costs of production and potential prices for the WHO Essential Medicines List","volume":"3","author":"Hill","year":"2018","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0010","series-title":"The Selection and Use of Essential Medicines: Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (Including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children)","author":"Organization WH","year":"2019"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0025","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/jth.14820","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Arachchillage","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0030","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.04.148_bb0035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/jth.14781","article-title":"Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia","volume":"18","author":"Lillicrap","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0045","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood J."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.04.148_bb0050","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/bjh.16725","article-title":"Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"189","author":"Xiong","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0055","first-page":"414","article-title":"Low-molecular-weight heparin treatment for acute lung injury\/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials","volume":"11","author":"Li","year":"2018","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.04.148_bb0060","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cts.12880","article-title":"The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study","volume":"13","author":"Shi","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0065","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jth.14821","article-title":"The versatile heparin in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0070","first-page":"1","article-title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients","author":"Testa","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0075","first-page":"1","article-title":"Management of thrombotic complications in COVID-19: an update","author":"Hajra","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ijbiomac.2021.04.148_bb0080","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin","volume":"120","author":"Mycroft-West","year":"2020","journal-title":"Throm. Haemos."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0085","article-title":"ACE2-independent interaction of SARS-CoV-2 spike protein to human epithelial cells can be inhibited by unfractionated heparin","author":"Partridge","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-00192-8","article-title":"Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro","volume":"6","author":"Kwon","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0095","first-page":"109743","article-title":"The old but new: can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?","author":"AB","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0100","article-title":"In silico identification and validation of inhibitors of the interaction between neuropilin receptor 1 and SARS-CoV-2 spike protein","author":"Perez-Miller","year":"2020","journal-title":"Biorxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0105","article-title":"SARS-CoV-2 infection and transmission depends on heparan sulfates and is blocked by low molecular weight heparins","author":"Bermejo-Jambrina","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0110","article-title":"Synthetic heparan sulfate mimetic pixatimod (PG545) potently inhibits SARS-CoV-2 by disrupting the spike-ACE2 interaction","author":"Guimond","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymeth.2021.01.003","article-title":"Bisindolylmaleimide IX: a novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays","author":"Gupta","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0120","series-title":"Bisindolylmaleimide IX: A Novel Anti-SARS-CoV2 Agent Targeting Viral Main Protease 3CLpro Demonstrated by Virtual Screening and In Vitro Assays","author":"Gupta","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0125","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jmb.2009.10.064","article-title":"Semi-rigid solution structures of heparin by constrained X-ray scattering modelling: new insight into heparin\u2013protein complexes","volume":"395","author":"Khan","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0135","series-title":"Small-Molecule Drug Discovery Suite 2020\u20131","volume":"2020","author":"Schrodinger","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0140","series-title":"Release 2020\u20132: Maestro","author":"Schrodinger","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0145","series-title":"2: Schr\u00f6dinger Suite 2020\u20132 Glide","author":"Release S","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0150","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0155","series-title":"Heparin- Century Prog","first-page":"211","article-title":"Adverse effects of heparin","author":"Alban","year":"2012"},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.04.148_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01987-20","article-title":"Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives","volume":"95","author":"Tandon","year":"2021","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.04.148_bb0165","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0170","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.7861\/clinmed.2020-0351","article-title":"Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19","volume":"20","author":"Conzelmann","year":"2020","journal-title":"Clin. Med."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0175","article-title":"SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner","author":"Liu","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03148-2","article-title":"Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence","volume":"24","author":"Van Haren","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0185","article-title":"Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line","author":"Partridge","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0190","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/brv.12034","article-title":"Glycosaminoglycans in infectious disease","volume":"88","author":"Kamhi","year":"2013","journal-title":"Biol. Rev."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0195","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0166-3542(87)90018-0","article-title":"Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro","volume":"7","author":"Ito","year":"1987","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00002030-199402000-00005","article-title":"Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding","volume":"8","author":"Harrop","year":"1994","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0205","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/acs.biochem.8b01267","article-title":"Glycosaminoglycan compositional analysis of relevant tissues in Zika virus pathogenesis and in vitro evaluation of heparin as an antiviral against Zika virus infection","volume":"58","author":"Kim","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/viro.1999.9633","article-title":"Analysis of the steps involved in dengue virus entry into host cells","volume":"257","author":"Hung","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0166-3542(02)00095-5","article-title":"Heparin inhibits dengue-2 virus infection of five human liver cell lines","volume":"56","author":"Lin","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejpb.2014.05.007","article-title":"Auto-associative heparin nanoassemblies: a biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV","volume":"88","author":"Lembo","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0225","first-page":"129","article-title":"Trend of respiratory pathogens during the COVID-19 epidemic","volume":"104470","author":"Sberna","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0230","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab129","article-title":"Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: a case report","author":"Zucman","year":"2021","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0235","series-title":"Risk Assessment: Risk Related to the Spread of New SARS-CoV-2 Variants of Concern in the EU\/EEA\u2014First Update","year":"2021"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0240","unstructured":"WHO WHO SARS-CoV-2 variant\u2014United Kingdom of Great Britain and Northern Ireland. https:\/\/www.who.int\/csr\/don\/21-december-2020-sars-cov2-variant-united-kingdom\/en."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00007-4","article-title":"First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020","author":"Fiorentini","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0250","article-title":"Introduction of the South African SARS-CoV-2 variant 501Y. V2 into the UK","author":"Tang","year":"2021","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0255","first-page":"1","article-title":"SARS-CoV-2 501Y. V2 escapes neutralization by south African COVID-19 donor plasma","author":"Wibmer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0260","series-title":"European Centre for Disease Prevention and Control, Rapid Risk Assessment: Detection of new SARS-CoV-2 variants related to mink, ECDC, Stockholm","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0265","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jama.2020.27124","article-title":"Genetic variants of SARS-CoV-2\u2014what do they mean?","volume":"325","author":"Lauring","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ijbiomac.2021.04.148_bb0270","doi-asserted-by":"crossref","first-page":"e00119","DOI":"10.1128\/JVI.00119-21","article-title":"Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil","volume":"95","author":"Voloch","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0275","article-title":"Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings","author":"Faria","year":"2021","journal-title":"Virological"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0280","series-title":"Spike E484K Mutation in the First SARS-CoV-2 Reinfection Case Confirmed in Brazil, 2020","first-page":"2021","volume":"10","author":"Resende","year":"2021"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0285","series-title":"New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil","year":"2021"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20321-x","article-title":"Stabilizing the closed SARS-CoV-2 spike trimer","volume":"12","author":"Juraszek","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.04.148_bb0295","first-page":"108630","article-title":"D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1\/S2 junction","volume":"34","author":"Gobeil","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0305","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0310","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1160\/TH09-02-0091","article-title":"Heparin, heparan sulfate and heparanase in inflammatory reactions","volume":"102","author":"Li","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0315","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1172\/JCI200113799","article-title":"Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry","volume":"108","author":"Shukla","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0320","first-page":"181","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"104873","author":"Kim","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0325","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ijbiomac.2020.09.184","article-title":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica","volume":"163","author":"Jin","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"6 Part -II","key":"10.1016\/j.ijbiomac.2021.04.148_bb0330","first-page":"2129","article-title":"Evaluation of Safety and Efficacy of Quick Penetrating Heparin Solution (1000 IU\/ml) in Prevention of Intravenous Cannula Related Thrombophlebitis: A Prospective, Randomized, Comparative, Parallel Group Clinical Study","volume":"6","author":"Pandya","year":"2019","journal-title":"Indian J Anesth Analg."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0335","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0378-5173(94)00143-X","article-title":"Effects of some non-toxic penetration enhancers on in vitro heparin skin permeation from gel vehicles","volume":"111","author":"Bonina","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0340","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1177\/0003319706297740","article-title":"Topical heparin: new observations","volume":"58","author":"Cesarone","year":"2007","journal-title":"Angiology"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0345","first-page":"3","article-title":"Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer-blind, placebo-controlled randomized study","volume":"53","author":"Belcaro","year":"2011","journal-title":"Panminerva Med."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cosmetics3040037","article-title":"Lipid self-assemblies and nanostructured emulsions for cosmetic formulations","volume":"3","author":"Kulkarni","year":"2016","journal-title":"Cosmetics"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0355","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1021\/acs.langmuir.7b02486","article-title":"Self-assembled lipid cubic phase and cubosomes for the delivery of aspirin as a model drug","volume":"33","author":"Kulkarni","year":"2017","journal-title":"Langmuir"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0360","article-title":"Can nebulised heparin reduce time to extubation in SARS CoV 2 the CHARTER study protocol","author":"Dixon","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0365","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2165\/00044011-200828100-00001","article-title":"Topically applied heparins for the treatment of vascular disorders","volume":"28","author":"Vecchio","year":"2008","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijbiomac.2021.04.148_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05421","article-title":"Aptamer BC 007-efficient binder of spreading-crucial SARS-CoV-2 proteins","volume":"6","author":"Weisshoff","year":"2020","journal-title":"Heliyon"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302100920X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181302100920X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:47:44Z","timestamp":1758876464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014181302100920X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":74,"alternative-id":["S014181302100920X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.04.148","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.04.148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}